Loxo Oncology Policy and Protocols for Access to Investigational Agents

Cancer is a life-threatening illness that is often poorly treated by available therapies. Loxo Oncology was founded to address this unmet medical need. Our product pipeline consists of investigational therapies that are currently being tested in clinical trials and have not yet been approved by the US Food and Drug Administration (FDA) or other regulatory bodies for commercial sale. We have conducted and are conducting research on our investigational product pipeline so that we can better understand how these investigational therapies work, which cancers in humans are most likely to benefit from these investigational therapies, and how to understand fully the safety and efficacy of the investigational therapies.

Patients with cancer often exhaust standard treatment options and seek out investigational therapies being tested in clinical trials. Sometimes these investigational therapies may be available to them as part of a clinical trial. People who take part in clinical trials help society by contributing to medical research, the development of new therapies, and the advancement of patient care. Other times, patients may not be able to participate in a clinical trial. When patients are not able to participate in a clinical trial, physicians can request drug companies like Loxo to make these investigational therapies available to their patients outside of clinical trials.

Loxo Oncology is committed to helping patients who have failed available therapies and may benefit from treatment access to the investigational therapies that we are developing in a manner that is both scientifically and ethically responsible. This Loxo Oncology Policy for Access to Investigational Agents describes the principles and government regulations that we will follow when considering a request.

1. The investigational therapy must be in **active clinical development**.

Loxo Oncology must be actively studying the investigational therapy in human subjects. In this way, Loxo Oncology is able to comply with local regulations regarding manufacturing, preclinical safety and reporting obligations. Restricting access to investigational therapies with active clinical programs also ensures that there are Loxo personnel who are trained and responsible for the safe release of the investigational therapy.

2. Patients must be first considered for ongoing clinical trials of the investigational therapy. Treating physicians interested in treating their patient with Loxo investigational therapies in active clinical development must first try to **enroll their patients** in a clinical trial studying the investigational therapy. Clinical trials incorporate regular safety monitoring, and create a venue for investigator training on the potential risks of the investigational therapy. In addition, Loxo Oncology has a scientific and ethical obligation to complete clinical trials that could support FDA approval of the medicine. Clinical trials have the ability to establish clinical benefit for the investigational therapy, and thus transform an investigational therapy into an approved drug capable of offering benefit to a wider population.

3. The patient must have a serious, immediately life threatening disease or condition

4. There must be a positive benefit-risk ratio for the patient. The potential benefits to the patient seeking access to the investigational therapy must always outweigh the collective potential risks to the patient of offering the investigational therapy. In establishing the benefit-risk ratio, Loxo will consider the outcome of the disease itself.
5. The physician who requests access must be qualified, agree to directly supervise treatment, be willing to obtain an IND from FDA and otherwise comply with relevant US federal and state regulations.

6. The physician requesting access must provide:
   - A scientifically justified rationale for the theoretical benefit that the investigational therapy could provide
   - A statement that approved therapies typically used to treat the disease have been exhausted and the patient is no longer responsive to, or able to tolerate, these therapies
   - A statement that there are no other viable therapy options, including participation in ongoing relevant clinical trials

7. There must be sufficient clinical data to identify an appropriate dose (amount and frequency of the investigational therapy given) and appropriate formulation.

8. After meeting the needs of clinical trials and other existing patients on therapy, Loxo Oncology must have a sufficient supply of the investigational therapy to reasonably accommodate the likely duration of treatment.